Evaluation of marker gene expression as a potential predictive marker of leukopenic toxicity for inactivated influenza vaccines

The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in the Japanese Minimum Requirements for Biological Products. LTT assesses the reduced leukocyte levels in murine peripheral blood after HAv adm...

Full description

Saved in:
Bibliographic Details
Published inBiologicals Vol. 50; pp. 100 - 108
Main Authors Sasaki, Eita, Momose, Haruka, Hiradate, Yuki, Furuhata, Keiko, Takai, Mamiko, Kamachi, Kazunari, Asanuma, Hideki, Ishii, Ken J., Mizukami, Takuo, Hamaguchi, Isao
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.11.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in the Japanese Minimum Requirements for Biological Products. LTT assesses the reduced leukocyte levels in murine peripheral blood after HAv administration. However, they require large numbers of animals, and therefore it would be beneficial to develop a more accurate and sensitive alternative method. In this study, we selected biomarkers of leukocyte reduction from 18 previously identified marker genes that were associated with an abnormal toxicity test (ATT). Among these 18 genes, the expressions of 15 marker genes were strongly associated with leukocyte reduction levels. A stepwise single addition multiple regression analysis was used to further extract the genes responsible for leukocyte reduction, with significant (p < 0.25) regression coefficients. The expression of 7 genes significantly predicted the leukocyte reduction. The prediction accuracy of this approach was approximately >90% (mean) for the direct measurement of leukocyte numbers. These results indicate that the expression of these 18 previously identified genes can provide information for both ATT and LTT.
AbstractList The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in the Japanese Minimum Requirements for Biological Products. LTT assesses the reduced leukocyte levels in murine peripheral blood after HAv administration. However, they require large numbers of animals, and therefore it would be beneficial to develop a more accurate and sensitive alternative method. In this study, we selected biomarkers of leukocyte reduction from 18 previously identified marker genes that were associated with an abnormal toxicity test (ATT). Among these 18 genes, the expressions of 15 marker genes were strongly associated with leukocyte reduction levels. A stepwise single addition multiple regression analysis was used to further extract the genes responsible for leukocyte reduction, with significant (p < 0.25) regression coefficients. The expression of 7 genes significantly predicted the leukocyte reduction. The prediction accuracy of this approach was approximately >90% (mean) for the direct measurement of leukocyte numbers. These results indicate that the expression of these 18 previously identified genes can provide information for both ATT and LTT.
The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in the Japanese Minimum Requirements for Biological Products. LTT assesses the reduced leukocyte levels in murine peripheral blood after HAv administration. However, they require large numbers of animals, and therefore it would be beneficial to develop a more accurate and sensitive alternative method. In this study, we selected biomarkers of leukocyte reduction from 18 previously identified marker genes that were associated with an abnormal toxicity test (ATT). Among these 18 genes, the expressions of 15 marker genes were strongly associated with leukocyte reduction levels. A stepwise single addition multiple regression analysis was used to further extract the genes responsible for leukocyte reduction, with significant (p < 0.25) regression coefficients. The expression of 7 genes significantly predicted the leukocyte reduction. The prediction accuracy of this approach was approximately >90% (mean) for the direct measurement of leukocyte numbers. These results indicate that the expression of these 18 previously identified genes can provide information for both ATT and LTT.
The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in the Japanese Minimum Requirements for Biological Products. LTT assesses the reduced leukocyte levels in murine peripheral blood after HAv administration. However, they require large numbers of animals, and therefore it would be beneficial to develop a more accurate and sensitive alternative method. In this study, we selected biomarkers of leukocyte reduction from 18 previously identified marker genes that were associated with an abnormal toxicity test (ATT). Among these 18 genes, the expressions of 15 marker genes were strongly associated with leukocyte reduction levels. A stepwise single addition multiple regression analysis was used to further extract the genes responsible for leukocyte reduction, with significant (p < 0.25) regression coefficients. The expression of 7 genes significantly predicted the leukocyte reduction. The prediction accuracy of this approach was approximately >90% (mean) for the direct measurement of leukocyte numbers. These results indicate that the expression of these 18 previously identified genes can provide information for both ATT and LTT.The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in the Japanese Minimum Requirements for Biological Products. LTT assesses the reduced leukocyte levels in murine peripheral blood after HAv administration. However, they require large numbers of animals, and therefore it would be beneficial to develop a more accurate and sensitive alternative method. In this study, we selected biomarkers of leukocyte reduction from 18 previously identified marker genes that were associated with an abnormal toxicity test (ATT). Among these 18 genes, the expressions of 15 marker genes were strongly associated with leukocyte reduction levels. A stepwise single addition multiple regression analysis was used to further extract the genes responsible for leukocyte reduction, with significant (p < 0.25) regression coefficients. The expression of 7 genes significantly predicted the leukocyte reduction. The prediction accuracy of this approach was approximately >90% (mean) for the direct measurement of leukocyte numbers. These results indicate that the expression of these 18 previously identified genes can provide information for both ATT and LTT.
Author Kamachi, Kazunari
Hamaguchi, Isao
Furuhata, Keiko
Asanuma, Hideki
Mizukami, Takuo
Momose, Haruka
Takai, Mamiko
Hiradate, Yuki
Sasaki, Eita
Ishii, Ken J.
Author_xml – sequence: 1
  givenname: Eita
  surname: Sasaki
  fullname: Sasaki, Eita
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan
– sequence: 2
  givenname: Haruka
  surname: Momose
  fullname: Momose, Haruka
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan
– sequence: 3
  givenname: Yuki
  surname: Hiradate
  fullname: Hiradate, Yuki
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan
– sequence: 4
  givenname: Keiko
  surname: Furuhata
  fullname: Furuhata, Keiko
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan
– sequence: 5
  givenname: Mamiko
  surname: Takai
  fullname: Takai, Mamiko
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan
– sequence: 6
  givenname: Kazunari
  surname: Kamachi
  fullname: Kamachi, Kazunari
  organization: Department of Bacteriology II, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan
– sequence: 7
  givenname: Hideki
  surname: Asanuma
  fullname: Asanuma, Hideki
  organization: Influenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208–0011, Japan
– sequence: 8
  givenname: Ken J.
  surname: Ishii
  fullname: Ishii, Ken J.
  organization: Laboratory of Adjuvant Innovation, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan
– sequence: 9
  givenname: Takuo
  surname: Mizukami
  fullname: Mizukami, Takuo
  email: tmiz@nih.go.jp
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan
– sequence: 10
  givenname: Isao
  surname: Hamaguchi
  fullname: Hamaguchi, Isao
  organization: Department of Safety Research on Blood and Biological Products, National Institute of Infectious Disease, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28838806$$D View this record in MEDLINE/PubMed
BookMark eNqNkUtv3CAUha0qVfNo_0JFd93YvRjGmFVVjdKHFKmb7BHGl4iJB1zAoySb_vXiTlJV3TQbuILvHME559WJDx6r6h2FhgLtPuyawYUp3Dijp9S0QEUDfQPAXlRnFOSm7lkLJ-vMNzWFTXdanae0A6CUC_6qOm37nvU9dGfVz8uDnhadXfAkWLLX8RYjuUGPBO_miCmtNzoRTeaQ0WenJ1LOR2eyO-CToEgnXG7DjN4ZksOdMy7fExsicV6vqM44ltlOC_oHTQ7aGOcxva5e2vIJfPO4X1TXny-vt1_rq-9fvm0_XdWGiy7XaKwE0Y4gjUBjWskZY2gGriWnWmBrGQcqO-yGXkMnrdD9gEwMsOFoLbuo3h9t5xh-LJiy2rtkcJq0x7AkVTKEFrik4r8olawt6ZW1oG8f0WXY46jm6Eoe9-op3gLII2BiSCmi_YNQUGuVaqf-qnJ9hlDQq1Jl0X78R1si_V1UjtpNz3LYHh2wBHtwGFUyDr0p5UU0WY3BPcPlF6puxY0
CitedBy_id crossref_primary_10_3389_fimmu_2020_02171
crossref_primary_10_3390_vaccines12060583
crossref_primary_10_1038_s41598_019_52686_5
crossref_primary_10_1080_17425255_2020_1807936
crossref_primary_10_1016_j_vaccine_2018_10_009
Cites_doi 10.1016/j.virusres.2004.02.029
10.1016/j.vaccine.2016.12.036
10.7883/yoken1952.28.37
10.1371/journal.pone.0101835
10.1038/nrmicro979
10.1073/pnas.1319268111
10.1016/j.vaccine.2008.02.031
10.4161/hv.22950
10.1038/4401099a
10.1371/journal.pone.0124392
10.1016/S0140-6736(03)15014-3
10.1016/j.vaccine.2013.02.016
ContentType Journal Article
Copyright 2017 International Alliance for Biological Standardization
Copyright © 2017 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.
Copyright_xml – notice: 2017 International Alliance for Biological Standardization
– notice: Copyright © 2017 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.
DBID AAYXX
CITATION
NPM
7X8
7S9
L.6
DOI 10.1016/j.biologicals.2017.08.003
DatabaseName CrossRef
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList PubMed

AGRICOLA
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1095-8320
EndPage 108
ExternalDocumentID 28838806
10_1016_j_biologicals_2017_08_003
S1045105617300982
Genre Journal Article
GroupedDBID ---
--K
--M
.~1
0R~
1B1
1RT
1~.
1~5
23N
4.4
457
4G.
53G
5GY
5VS
6J9
7-5
71M
8P~
9JM
AAAJQ
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AAXUO
ABBQC
ABFNM
ABFRF
ABGSF
ABJNI
ABLVK
ABMAC
ABMZM
ABUDA
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACRLP
ADBBV
ADEZE
ADFGL
ADMUD
ADUVX
AEBSH
AEFWE
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGEKW
AGHFR
AGRDE
AGUBO
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
CJTIS
COF
CS3
DM4
DOVZS
DU5
EBS
EFBJH
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEJ
HMG
HMK
HMO
HVGLF
HZ~
IHE
J1W
KOM
LCYCR
LG5
LUGTX
LZ5
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SAE
SDF
SDG
SDP
SES
SEW
SIN
SPCBC
SSH
SSI
SSU
SSZ
T5K
UNMZH
WUQ
XPP
ZMT
~G-
~KM
AAHBH
AATTM
AAXKI
AAYWO
AAYXX
ABWVN
ACIEU
ACRPL
ACVFH
ADCNI
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AGRNS
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
CITATION
EFKBS
NPM
7X8
7S9
L.6
ID FETCH-LOGICAL-c476t-ecf9072d09c7ecc294333ecb4a941a7e2f340196e6b8a069f7a8be37b054eff3
IEDL.DBID .~1
ISSN 1045-1056
1095-8320
IngestDate Thu Jul 10 20:07:20 EDT 2025
Fri Jul 11 06:52:54 EDT 2025
Mon Jul 21 05:57:43 EDT 2025
Thu Apr 24 23:03:50 EDT 2025
Tue Jul 01 03:56:50 EDT 2025
Fri Feb 23 02:34:24 EST 2024
IsPeerReviewed true
IsScholarly true
Keywords ATT
LTT
JMR
SA
RE
WBC
Safety test
QGP
HAv
WPV
Influenza vaccine
Leukopenic toxicity test
Marker gene
Language English
License Copyright © 2017 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c476t-ecf9072d09c7ecc294333ecb4a941a7e2f340196e6b8a069f7a8be37b054eff3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
PMID 28838806
PQID 1932838932
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_2010204917
proquest_miscellaneous_1932838932
pubmed_primary_28838806
crossref_primary_10_1016_j_biologicals_2017_08_003
crossref_citationtrail_10_1016_j_biologicals_2017_08_003
elsevier_sciencedirect_doi_10_1016_j_biologicals_2017_08_003
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2017
2017-11-00
2017-Nov
20171101
PublicationDateYYYYMMDD 2017-11-01
PublicationDate_xml – month: 11
  year: 2017
  text: November 2017
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Biologicals
PublicationTitleAlternate Biologicals
PublicationYear 2017
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References National Institute of Infectious Diseases (bib1) 2006
Mizukami, Imai, Hamaguchi, Kawamura, Momose, Naito (bib3) 2008; 24
Kurokawa, Ishida, Asakawa, Iwasa, Goto (bib2) 1975; 1
Mizukami, Momose, Kuramitsu, Takizawa, Araki, Furuhata (bib5) 2014; 9
Stephenson, Nicholson, Glück, Mischler, Newman, Palache (bib9) 2003; 362
Ato, Takahashi, Fujii, Hashimoto, Kaji, Itamura (bib14) 2013; 31
Kobiyama, Aoshi, Narita, Kuroda, Hayashi, Tetsutani (bib7) 2014; 111
Wood, Robertson (bib12) 2004; 2
Dennis (bib13) 2006; 440
Momose, Mizukami, Kuramitsu, Takizawa, Masumi, Araki (bib6) 2015; 10
Tougan, Aoshi, Coban, Katakai, Kai, Yasutomi (bib8) 2013; 9
WHO (bib11)
Hehme, Engelmann, Kuenzel, Neumeier, Saenger (bib10) 2004; 103
Sasaki, Kuramitsu, Momose, Kobiyama, Aoshi, Yamada (bib4) 2017; 35
Momose (10.1016/j.biologicals.2017.08.003_bib6) 2015; 10
Mizukami (10.1016/j.biologicals.2017.08.003_bib5) 2014; 9
National Institute of Infectious Diseases (10.1016/j.biologicals.2017.08.003_bib1) 2006
Dennis (10.1016/j.biologicals.2017.08.003_bib13) 2006; 440
Sasaki (10.1016/j.biologicals.2017.08.003_bib4) 2017; 35
Tougan (10.1016/j.biologicals.2017.08.003_bib8) 2013; 9
Mizukami (10.1016/j.biologicals.2017.08.003_bib3) 2008; 24
Kurokawa (10.1016/j.biologicals.2017.08.003_bib2) 1975; 1
Hehme (10.1016/j.biologicals.2017.08.003_bib10) 2004; 103
Wood (10.1016/j.biologicals.2017.08.003_bib12) 2004; 2
Ato (10.1016/j.biologicals.2017.08.003_bib14) 2013; 31
Kobiyama (10.1016/j.biologicals.2017.08.003_bib7) 2014; 111
WHO (10.1016/j.biologicals.2017.08.003_bib11)
Stephenson (10.1016/j.biologicals.2017.08.003_bib9) 2003; 362
References_xml – volume: 111
  start-page: 3086
  year: 2014
  end-page: 3091
  ident: bib7
  article-title: Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist
  publication-title: Proc Natl Acad Sci U. S. A
– volume: 9
  start-page: 283
  year: 2013
  end-page: 290
  ident: bib8
  article-title: TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models
  publication-title: Hum Vaccin Immunother
– year: 2006
  ident: bib1
  article-title: Minimum requirements for biological products
– volume: 2
  start-page: 842
  year: 2004
  end-page: 847
  ident: bib12
  article-title: From lethal virus to life-saving vaccine development inactivated vaccines for pandemic influenza
  publication-title: Nat Rev Microb
– volume: 1
  start-page: 37
  year: 1975
  end-page: 52
  ident: bib2
  article-title: Toxicities of influenza vaccine: peripheral leukocytic response to live and inactivated influenza viruses in mice
  publication-title: Jpn J Med Sci Biol
– volume: 9
  start-page: e101835
  year: 2014
  ident: bib5
  article-title: System vaccinology for the evaluation of influenza vaccine safety by multiplex gene detection of novel biomarkers in a preclinical study and batch release test
  publication-title: PLoS One
– volume: 10
  start-page: e0124392
  year: 2015
  ident: bib6
  article-title: Establishment of a new quality control and vaccine safety test for influenza vaccines and adjuvants using gene expression profiling
  publication-title: PLoS One
– volume: 24
  start-page: 2270
  year: 2008
  end-page: 2283
  ident: bib3
  article-title: Application of DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation
  publication-title: Vaccine
– volume: 362
  start-page: 1959
  year: 2003
  end-page: 1966
  ident: bib9
  article-title: Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial
  publication-title: Lancet
– volume: 31
  start-page: 2184
  year: 2013
  end-page: 2190
  ident: bib14
  article-title: Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-α-dependent apoptosis
  publication-title: Vaccine
– volume: 103
  start-page: 163
  year: 2004
  end-page: 171
  ident: bib10
  article-title: Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use
  publication-title: Virus Res
– volume: 440
  start-page: 1099
  year: 2006
  ident: bib13
  article-title: Flu-vaccine makers toil to boost supply
  publication-title: Nature
– volume: 35
  start-page: 821
  year: 2017
  end-page: 830
  ident: bib4
  article-title: A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests
  publication-title: Vaccine
– ident: bib11
  article-title: Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines
– year: 2006
  ident: 10.1016/j.biologicals.2017.08.003_bib1
– ident: 10.1016/j.biologicals.2017.08.003_bib11
– volume: 103
  start-page: 163
  year: 2004
  ident: 10.1016/j.biologicals.2017.08.003_bib10
  article-title: Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use
  publication-title: Virus Res
  doi: 10.1016/j.virusres.2004.02.029
– volume: 35
  start-page: 821
  year: 2017
  ident: 10.1016/j.biologicals.2017.08.003_bib4
  article-title: A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2016.12.036
– volume: 1
  start-page: 37
  year: 1975
  ident: 10.1016/j.biologicals.2017.08.003_bib2
  article-title: Toxicities of influenza vaccine: peripheral leukocytic response to live and inactivated influenza viruses in mice
  publication-title: Jpn J Med Sci Biol
  doi: 10.7883/yoken1952.28.37
– volume: 9
  start-page: e101835
  year: 2014
  ident: 10.1016/j.biologicals.2017.08.003_bib5
  article-title: System vaccinology for the evaluation of influenza vaccine safety by multiplex gene detection of novel biomarkers in a preclinical study and batch release test
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0101835
– volume: 2
  start-page: 842
  year: 2004
  ident: 10.1016/j.biologicals.2017.08.003_bib12
  article-title: From lethal virus to life-saving vaccine development inactivated vaccines for pandemic influenza
  publication-title: Nat Rev Microb
  doi: 10.1038/nrmicro979
– volume: 111
  start-page: 3086
  year: 2014
  ident: 10.1016/j.biologicals.2017.08.003_bib7
  article-title: Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist
  publication-title: Proc Natl Acad Sci U. S. A
  doi: 10.1073/pnas.1319268111
– volume: 24
  start-page: 2270
  year: 2008
  ident: 10.1016/j.biologicals.2017.08.003_bib3
  article-title: Application of DNA microarray technology to influenza A/Vietnam/1194/2004 (H5N1) vaccine safety evaluation
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2008.02.031
– volume: 9
  start-page: 283
  year: 2013
  ident: 10.1016/j.biologicals.2017.08.003_bib8
  article-title: TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models
  publication-title: Hum Vaccin Immunother
  doi: 10.4161/hv.22950
– volume: 440
  start-page: 1099
  year: 2006
  ident: 10.1016/j.biologicals.2017.08.003_bib13
  article-title: Flu-vaccine makers toil to boost supply
  publication-title: Nature
  doi: 10.1038/4401099a
– volume: 10
  start-page: e0124392
  year: 2015
  ident: 10.1016/j.biologicals.2017.08.003_bib6
  article-title: Establishment of a new quality control and vaccine safety test for influenza vaccines and adjuvants using gene expression profiling
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0124392
– volume: 362
  start-page: 1959
  year: 2003
  ident: 10.1016/j.biologicals.2017.08.003_bib9
  article-title: Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(03)15014-3
– volume: 31
  start-page: 2184
  year: 2013
  ident: 10.1016/j.biologicals.2017.08.003_bib14
  article-title: Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-α-dependent apoptosis
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2013.02.016
SSID ssj0011474
Score 2.1535704
Snippet The leukopenic toxicity test (LTT) is used to evaluate the safety and lot-to-lot consistency of influenza hemagglutinin split vaccine (HAv) and is included in...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 100
SubjectTerms biomarkers
gene expression
genes
genetic markers
hemagglutinins
influenza
Influenza vaccine
influenza vaccines
leukocytes
Leukopenic toxicity test
Marker gene
mice
prediction
regression analysis
Safety test
toxicity
toxicity testing
Title Evaluation of marker gene expression as a potential predictive marker of leukopenic toxicity for inactivated influenza vaccines
URI https://dx.doi.org/10.1016/j.biologicals.2017.08.003
https://www.ncbi.nlm.nih.gov/pubmed/28838806
https://www.proquest.com/docview/1932838932
https://www.proquest.com/docview/2010204917
Volume 50
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS-QwEB_E48SX4z7U2_uQCL7WbZNs28C9yKLsfShyKvgW0jSBqtcublfUh7t__Wb6sZ4cguBT25ApYWYy-YVMfgOwLcwoj11KM82MAokLQKAy54MwV4mztKFoTkwPDuPJqfx2NjpbgnF_F4bSKrvY38b0Jlp3LcNOm8NpUQyPI6JGIQBMlOsqpTgsZUJevvN7keaBcL9hYqbOAfVega37HK-W6Ii0QczdUdKwefb1s_5fox7DoM1atP8aXnUgku2243wDS658Cy_bspK37-DP3oLCm1We_aIMnCuGnuKYu-kSX0tmZsywaVVTuhD-DNvzogl-vQCKXrr5BdXXKiyrq5vCImRniHJZUdJ9iGvEqTm-N2VO7gy7NpaO6WdrcLK_dzKeBF2hhcCiwurAWY97ZJ6HyqKBLFdSCOFsJo2SkUkc90ISj46Ls9SEsfKJSTMnkgzxnvNerMNyWZXuPbBMWakiy72PrJR5aizPeZiNhLUiDpN8AGmvWW07EnKqhXGp-2yzc_2PUTQZRVOdzFAMgC9Epy0Tx1OEvvTm0w_cSuOK8RTxrd7kGqcdnaWY0lXzmSbcmxLY44_3oUQDjjuwKBnARusvi5FTkWcMnfGH5w3wI6zSV3s58hMs11dz9xlRUp1tNtNgE17sjn_-OKLn1--Tw78bXxfZ
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7Chia9lLZJ2u1TgVzN2pL8EPQSQsKmSfaSDeQmZFkCt6m9ZL0h7aV_vTN-bFtKINCbsTVGaKTRJ2b0fQAHwsRF4jJaaSYOJG4AgcqdD8JCpc7SgaLNmF7MkumV_HwdX2_A0XAXhsoq-9jfxfQ2WvdvJv1oThZlObmMiBqFADBRrqsM4_AmsVPFI9g8PD2bztbJhEi2ZMzUPiCDLdj_XebVcR3RgBB5d5S2hJ6DhNa_29RDMLTdjk6ew7MeR7LDrqsvYMNVL-FJpyz5fQd-Hq9ZvFnt2TcqwrllOFkcc_d97WvFzJIZtqgbqhjCn-H7omzj32CApjdu9ZUktkrLmvq-tIjaGQJdVlZ0JeIOoWqBz63SyQ_D7oylTP1yF-Ynx_OjadBrLQRWpkkTOOvxmMyLUFn0keVKCiGczaVRMjKp415IotJxSZ6ZMFE-NVnuRJoj5HPeiz0YVXXlXgPLlZUqstz7yEpZZMbygod5LKwVSZgWY8iGkdW25yEnOYwbPRScfdF_OEWTUzRJZYZiDHxtuujIOB5j9Glwn_5rZmncNB5jvj-4XOPKo3SKqVy9WmqCvhnhPf5wG6o14HgIi9IxvOrmy7rnpPOM0TN5838d_Ajb0_nFuT4_nZ29haf0pbsr-Q5Gze3KvUfQ1OQf-kXxC9EeGPU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+marker+gene+expression+as+a+potential+predictive+marker+of+leukopenic+toxicity+for+inactivated+influenza+vaccines&rft.jtitle=Biologicals&rft.au=Sasaki%2C+Eita&rft.au=Momose%2C+Haruka&rft.au=Hiradate%2C+Yuki&rft.au=Furuhata%2C+Keiko&rft.date=2017-11-01&rft.eissn=1095-8320&rft.volume=50&rft.spage=100&rft_id=info:doi/10.1016%2Fj.biologicals.2017.08.003&rft_id=info%3Apmid%2F28838806&rft.externalDocID=28838806
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1045-1056&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1045-1056&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1045-1056&client=summon